Cargando…

Aberrant Hematopoiesis and Morbidity in Extremely Preterm Infants With Intrauterine Growth Restriction

Background and Objective: Intrauterine growth restriction (IUGR) poses additional challenges in extremely low gestational age newborns (ELGANs). We assessed disturbed hematopoiesis and morbidities associated with this disorder. Methods: This single-center retrospective case–control study compared pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Reibel, Nora J., Dame, Christof, Bührer, Christoph, Muehlbacher, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633541/
https://www.ncbi.nlm.nih.gov/pubmed/34869097
http://dx.doi.org/10.3389/fped.2021.728607
_version_ 1784607950752448512
author Reibel, Nora J.
Dame, Christof
Bührer, Christoph
Muehlbacher, Tobias
author_facet Reibel, Nora J.
Dame, Christof
Bührer, Christoph
Muehlbacher, Tobias
author_sort Reibel, Nora J.
collection PubMed
description Background and Objective: Intrauterine growth restriction (IUGR) poses additional challenges in extremely low gestational age newborns (ELGANs). We assessed disturbed hematopoiesis and morbidities associated with this disorder. Methods: This single-center retrospective case–control study compared perinatal hematological profiles, major morbidities, and mortality of 49 infants (gestational age <28 weeks, birth weight ≤ 3rd percentile, and compromised placental function) and 98 infants (birth weight >10th percentile) matched for gestational age, year, and sex. Results: IUGR-ELGANs had significantly elevated nucleated red blood cells and lower neutrophil and platelet counts at birth and on the third day of life. During the first week of life, IUGR-ELGANs received more red blood cell, platelet, and plasma transfusions and were more intensively treated with antibiotics. Rates of infections acquired during the first week (59.2 vs. 17.3%, p < 0.001), severe bronchopulmonary dysplasia or death (42.9 vs. 17.3%, p < 0.01), and mortality (36.7 vs. 7.1%, p < 0.001) were markedly elevated in IUGR-ELGANs, but not of hemorrhages or other morbidities. Conclusions: IUGR-ELGANs have high rates of acquired infections during the first week of life and display severe pulmonary morbidity leading to bronchopulmonary dysplasia or death. The high rate of transfusions observed in these infants warrants further scrutiny.
format Online
Article
Text
id pubmed-8633541
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86335412021-12-02 Aberrant Hematopoiesis and Morbidity in Extremely Preterm Infants With Intrauterine Growth Restriction Reibel, Nora J. Dame, Christof Bührer, Christoph Muehlbacher, Tobias Front Pediatr Pediatrics Background and Objective: Intrauterine growth restriction (IUGR) poses additional challenges in extremely low gestational age newborns (ELGANs). We assessed disturbed hematopoiesis and morbidities associated with this disorder. Methods: This single-center retrospective case–control study compared perinatal hematological profiles, major morbidities, and mortality of 49 infants (gestational age <28 weeks, birth weight ≤ 3rd percentile, and compromised placental function) and 98 infants (birth weight >10th percentile) matched for gestational age, year, and sex. Results: IUGR-ELGANs had significantly elevated nucleated red blood cells and lower neutrophil and platelet counts at birth and on the third day of life. During the first week of life, IUGR-ELGANs received more red blood cell, platelet, and plasma transfusions and were more intensively treated with antibiotics. Rates of infections acquired during the first week (59.2 vs. 17.3%, p < 0.001), severe bronchopulmonary dysplasia or death (42.9 vs. 17.3%, p < 0.01), and mortality (36.7 vs. 7.1%, p < 0.001) were markedly elevated in IUGR-ELGANs, but not of hemorrhages or other morbidities. Conclusions: IUGR-ELGANs have high rates of acquired infections during the first week of life and display severe pulmonary morbidity leading to bronchopulmonary dysplasia or death. The high rate of transfusions observed in these infants warrants further scrutiny. Frontiers Media S.A. 2021-11-12 /pmc/articles/PMC8633541/ /pubmed/34869097 http://dx.doi.org/10.3389/fped.2021.728607 Text en Copyright © 2021 Reibel, Dame, Bührer and Muehlbacher. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Reibel, Nora J.
Dame, Christof
Bührer, Christoph
Muehlbacher, Tobias
Aberrant Hematopoiesis and Morbidity in Extremely Preterm Infants With Intrauterine Growth Restriction
title Aberrant Hematopoiesis and Morbidity in Extremely Preterm Infants With Intrauterine Growth Restriction
title_full Aberrant Hematopoiesis and Morbidity in Extremely Preterm Infants With Intrauterine Growth Restriction
title_fullStr Aberrant Hematopoiesis and Morbidity in Extremely Preterm Infants With Intrauterine Growth Restriction
title_full_unstemmed Aberrant Hematopoiesis and Morbidity in Extremely Preterm Infants With Intrauterine Growth Restriction
title_short Aberrant Hematopoiesis and Morbidity in Extremely Preterm Infants With Intrauterine Growth Restriction
title_sort aberrant hematopoiesis and morbidity in extremely preterm infants with intrauterine growth restriction
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633541/
https://www.ncbi.nlm.nih.gov/pubmed/34869097
http://dx.doi.org/10.3389/fped.2021.728607
work_keys_str_mv AT reibelnoraj aberranthematopoiesisandmorbidityinextremelypreterminfantswithintrauterinegrowthrestriction
AT damechristof aberranthematopoiesisandmorbidityinextremelypreterminfantswithintrauterinegrowthrestriction
AT buhrerchristoph aberranthematopoiesisandmorbidityinextremelypreterminfantswithintrauterinegrowthrestriction
AT muehlbachertobias aberranthematopoiesisandmorbidityinextremelypreterminfantswithintrauterinegrowthrestriction